Synthesis and antitumoral activity of novel analogues monastrol–fatty acids against glioma cells† †Electronic supplementary information (ESI) available: 1H and 13C NMR spectra of the compounds. See DOI: 10.1039/c8md00169c

• Published in: MedChemComm Vol. 9; no. 8; pp. 1282 - 1288
• Main Authors: De Oliveira, Franciele S., De Oliveira, Patrick M., Farias, Luana M., Brinkerhoff, Rafael C., Sobrinho, Rui Carlos M. A., Treptow, Tamara M., Montes D'Oca, Caroline R., Marinho, Marcelo A. G., Hort, Mariana A., Horn, Ana P., Russowsky, Dennis, Montes D'Oca, Marcelo G.
• Format: Journal Article
• Language: English
• Published: Royal Society of Chemistry 30.05.2018
• Subjects: Chemistry
• ISSN: 2040-2503; 2040-2511
• DOI: 10.1039/c8md00169c

Heterocyclic–fatty acid derivatives are a new class of compounds with a broad range of biological activities. Monastrol is a small cell-permeable heterocyclic molecule that is recognized as an inhibitor of mitotic kinesin Eg5. Heterocyclic–fatty acid derivatives are a new class of compounds with a broad range of biological activities. This work describes a comparative study of the in vitro antitumoral activity of a series of new long-chain monastrol analogues against rat glioblastoma cells. The novel analogues C6-substituted monastrol and oxo-monastrol were synthesized via Biginelli multicomponent condensation of fatty β-ketoester in good yields using a simple approach catalyzed by nontoxic and free-metal sulfamic acid. Following synthesis, their in vitro antitumoral activities were investigated. Notably, all analogues tested were active against rat glioblastoma cells. Superior activity was observed by analogues derived from palmitic and stearic fatty acid chains; these compounds were the most potent molecules, showing 13-fold higher potency than monastrol with IC 50 values of 5.11 and 6.85 μM, respectively. These compounds could provide promising new lead derivatives for more potent antitumor drugs.